Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 8,366 | 8,319 | 8,692 | 8,834 | 8,489 |
| Income taxes - deferred | -85 | -177 | -95 | -196 | 20 |
| Accounts receivable | -1,701 | 1,064 | -763 | 91 | -600 |
| Accounts payable and accrued liabilities | -521 | 1,420 | -641 | 156 | 3,617 |
| Other Working Capital | 575 | 983 | 166 | -5 | 356 |
| Other Operating Activity | -3,966 | -7,589 | -3,838 | -4,729 | -8,370 |
| Operating Cash Flow | $2,668 | $4,020 | $3,521 | $4,151 | $3,512 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -27 | 0 | -9 | -12 | -15 |
| Purchase Sale Intangibles | -108 | 0 | -11 | -10,000 | -66 |
| Investing Cash Flow | $-135 | $0 | $-20 | $-10,012 | $-81 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,547 | -2,282 | -2,551 | -1,551 | -3,180 |
| Common Stock Repurchased | -185 | -184 | -350 | -270 | -357 |
| Dividend Paid | -1,216 | -1,182 | -1,193 | -1,220 | -1,267 |
| Other Financing Activity | 0 | 134 | 0 | 9,373 | 7 |
| Financing Cash Flow | $-2,948 | $-3,514 | $-4,094 | $6,332 | $-4,797 |
| Exchange Rate Effect | 133 | -15 | 37 | -352 | -138 |
| Beginning Cash Position | 21,214 | 20,723 | 21,279 | 21,160 | 22,664 |
| End Cash Position | 20,932 | 21,214 | 20,723 | 21,279 | 21,160 |
| Net Cash Flow | $-415 | $506 | $-593 | $471 | $-1,366 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,668 | 4,020 | 3,521 | 4,151 | 3,512 |
| Capital Expenditure | N/A | N/A | -20 | -10,012 | -81 |
| Free Cash Flow | 2,668 | 4,020 | 3,501 | -5,861 | 3,431 |